Biopharmaceutical newcomer Intra-Cellular surged over 25% before the market opened! It is reported that Johnson & Johnson is in talks to acquire the company, reigniting a wave of Medical mergers and acquisitions.

Johnson & Johnson is in talks to acquire the biopharmaceutical company Intra-Cellular Therapies Inc., which focuses on treating central nervous system diseases, and both parties may reach an agreement as early as this week.

Zhitong Finance17:27

Intra-Cellular surged nearly 35%! Johnson & Johnson plans to spend $10 billion to acquire the company, marking the largest Biotechnology merger in nearly two years!

This is the largest Trade in the biotechnology Industry in nearly two years, and it is also the first Biomedical merger exceeding 10 billion dollars since 2024, indicating a resurgence in merger and acquisition activities in the Medical Care sector. Goldman Sachs stated that the potential financing capacity of large Biopharmaceutical companies is at least 500 billion dollars, providing significant operational space for R&D investment, merger expansion, and more.

wallstreetcnjust now

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires36minutes ago

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

WSJ21:39

US stock outlook | Wall Street begins to discuss the possibility of interest rate hikes! The three major index futures collectively weakened; Intra-Cellular surged nearly 35% in pre-market trading! It will be acquired by Johnson & Johnson for billions.

Tesla fell 3% before the market opened, as the largest Retirement Fund in Europe liquidated its shares; the yield on the 10-year US Treasury is aiming for 5%! The Global bond market is in turmoil.

Futu News21:21

Johnson & Johnson (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for sale in the domestic market.

Johnson & Johnson (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for sale in the domestic market.

Zhitong Finance21:21